^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Breast Cancer
    Drug:capecitabine (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    02/22/2019
    Excerpt:
    XELODA (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for...Metastatic Breast Cancer...As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    04/20/2012
    Excerpt:
    Capecitabine Teva is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.